美国成人一次性普遍筛查慢性乙型肝炎的成本效果
研究采用马尔可夫模型评估美国18-69岁成人一次性普遍HBsAg筛查联合监测治疗的成本效果,对比现行筛查实践。在未诊断CHB患病率0.24%的假设下,若抗病毒药物年费用低于894美元,普遍筛查可节省成本,并减少肝硬化、肝癌、肝移植和乙肝相关死亡。结论认为普遍筛查具有成本效果且可能节省成本。
要点
- 18-69岁成人一次性普遍HBsAg筛查在药物年费用低于894美元时较现行实践节省成本。
- 普遍筛查每10万成人可避免7.4例代偿期肝硬化、3.3例失代偿期肝硬化、5.5例肝细胞癌、1.9例肝移植和10.3例乙肝相关死亡。
核心结论
- 美国成人普遍HBsAg筛查慢性乙型肝炎具有成本效果,且可能较现行筛查建议节省成本。
研究设计与样本
- 研究使用马尔可夫模型计算一次性普遍筛查联合CHB监测治疗的成本、人群健康影响和成本效果,并与现行实践比较。
- 分析假设检测在常规医疗就诊时进行,治疗使用仿制替诺福韦或恩替卡韦,检测成本基于Medicare报销费率。
主要发现
- 在未诊断CHB患病率估计为0.24%时,若抗病毒药物年费用低于894美元,18-69岁成人普遍HBsAg筛查较现行实践节省成本。
- 与现行实践相比,普遍筛查每10万成人可额外避免7.4例代偿期肝硬化、3.3例失代偿期肝硬化、5.5例肝细胞癌、1.9例肝移植和10.3例乙肝病毒相关死亡。
关键数值与推荐
- 未诊断CHB患病率估计为0.24%。
- 抗病毒药物年费用阈值低于894美元时普遍筛查节省成本。
临床怎么用
- 在常规医疗就诊时对18-69岁成人考虑一次性普遍HBsAg筛查,并衔接CHB监测与治疗。
- 若使用仿制替诺福韦或恩替卡韦且年药物费用低于894美元,普遍筛查可能节省成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An estimated 862 000 to 2.4 million people have chronic hepatitis B infection (CHB). Hepatitis B screening is recommended for pregnant women and populations with increased CHB risk. However, diagnosis rates remain low, with only 33% of people with CHB aware of their infection. This study aimed to assess the cost-effectiveness of universal adult screening for CHB. METHODS: We used a Markov model to calculate the costs, population health impact, and cost-effectiveness of 1-time universal screening and CHB monitoring and treatment compared with current practice. Sensitivity analysis was performed on model parameters to identify thresholds for cost-saving or cost-effectiveness based on a willingness to pay of $50 000/quality-adjusted life-year. The analysis assumed testing would be performed during routine healthcare visits and that generic tenofovir or entecavir would be dispensed for treatment. Testing costs were based on Medicare reimbursement rates. RESULTS: At an estimated 0.24% prevalence of undiagnosed CHB, universal hepatitis B surface antigen (HBsAg) screening in adults aged 18-69 years is cost-saving compared with current practice if antiviral treatment drug costs remain below $894/year. Compared with current practice, universal screening would avert an additional 7.4 cases of compensated cirrhosis, 3.3 cases of decompensated cirrhosis, 5.5 cases of hepatocellular carcinoma, 1.9 liver transplants, and 10.3 hepatitis B virus-related deaths at a saving of $263 000/100 000 adults screened. CONCLUSIONS: Universal HBsAg screening of adults in the US general population for CHB is cost-effective and likely cost-saving compared with current CHB screening recommendations.
引用
- Toy M, Hutton D, Harris AM, et al. Cost-Effectiveness of 1-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States. Clin Infect Dis. 2022. PMID: 33956937. doi:10.1093/cid/ciab405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。